IndustryCompany release

Lantheus Q3 revenue up 1.5% to $389.9M as FDA approves two products

🇺🇸 Lantheus Holdings, Inc. (LNTH) · Thu 05 Nov 2026

The radiopharmaceutical company reported third-quarter results, cited two FDA approvals and a CMS reimbursement decision, and suspended 2026 guidance because of its pending Curium merger.

Lantheus Holdings reported worldwide revenue of $389.9 million for the third quarter of 2026, a rise of 1.5%. Results were published on 5 November 2026. GAAP earnings per share were $0.33, against adjusted earnings per share of $1.68.

Two US regulatory decisions fell within the period. The FDA approved TAUKLARIFY, a tau PET imaging agent for adults with cognitive impairment who are being evaluated for Alzheimer's disease. The agency also gave final approval to BRAVNETSA, a lutetium Lu 177 dotatate product that it deemed bioequivalent and therapeutically equivalent to LUTATHERA for gastroenteropancreatic neuroendocrine tumours (GEP-NETs).

On reimbursement, the company said the Centers for Medicare & Medicaid Services granted pass-through status and a permanent HCPCS code for PYLARIFY TruVu, effective 1 October 2026. As general context, HCPCS codes are used in the US to identify products and services for billing, and pass-through status provides separate payment for eligible new products in the hospital outpatient setting.

Lantheus also suspended its 2026 financial guidance because of the pending merger with Curium, which it valued at up to about $8.0 billion. The summary available does not give further details of the transaction terms or its expected timing.

What it means for your team

  • Market-access teams should note the permanent HCPCS code and pass-through status for PYLARIFY TruVu, in effect from 1 October 2026.
  • The FDA's therapeutic equivalence determination for BRAVNETSA relative to LUTATHERA is relevant to anyone tracking competition in lutetium-based GEP-NET treatment.
  • The approval of TAUKLARIFY adds a tau PET agent to the diagnostic options for patients being assessed for Alzheimer's disease.
  • The Curium merger remains pending, and the company has withdrawn its 2026 guidance, so teams should watch for further regulatory and transaction updates.

Company's press release (SEC filing): Lantheus Holdings, Inc. ↗

Article written by VigiEye from the official source (Lantheus Holdings, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →